{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:11Z","timestamp":1777859591478,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Labetalol is an adrenergic antagonist used to manage blood pressure. Current package labeling and drug databases describe intravenous (IV) labetalol\u2019s hemodynamic effects to have an alpha-to-beta potency relationship of 1:7, denoting a predominantly negative cardiotropic effect, which differs from our clinical experience.\n                    <jats:bold>Objective:<\/jats:bold>\n                    The purpose of this study was to describe the hemodynamic effects of IV labetalol in clinical practice and compare those results to official references.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This was a retrospective, observational cohort study of patients undergoing evaluation and management for acute ischemic stroke in the emergency department. We included patients who received IV labetalol and excluded those experiencing intracerebral hemorrhage. The primary outcome was labetalol\u2019s alpha-to-beta relative clinical potency (RCP), calculated as the median \u0394SBP \/ \u0394HR, using nadir values within one hour of labetalol\u2019s administration.\n                    <jats:bold>Results:<\/jats:bold>\n                    Forty-two patients met criteria for analysis, with median age of 66\u00a0years and majority female sex (71%). Following a median dose of 10\u00a0mg, the median \u0394SBP was \u221235\u00a0mmHg and \u0394HR -9 beats per minute. The median alpha-to-beta RCP was approximately 7:2. Out of 42 patients, 10 experienced excessive reductions in SBP. This cohort exhibited neither new-onset bradycardia nor reflex tachycardia.\n                    <jats:bold>Conclusions and Relevance:<\/jats:bold>\n                    We clinically observed IV labetalol\u2019s alpha-to-beta potency ratio to be 7:2, significantly differing from the 1:7 ratio stated in official references. While this study has limitations, our findings highlight an inconsistency between real-world experience and nongeneralizable experimental results. We recommend revision of the official references that intend to guide clinician use of IV labetalol.\n                  <\/jats:p>","DOI":"10.1177\/08971900251370870","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T15:01:58Z","timestamp":1755961318000},"page":"179-183","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective Reappraisal of Labetalol\u2019s Hemodynamic Effects"],"prefix":"10.1177","volume":"39","author":[{"given":"Mary Margaret","family":"Rinker","sequence":"first","affiliation":[{"name":"University of Illinois at Chicago, Retzky College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Valadez","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, Retzky College of Pharmacy"},{"name":"University of Illinois Hospital and Health Sciences System (UI Health)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Petzel Gimbar","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, Retzky College of Pharmacy"},{"name":"University of Illinois Hospital and Health Sciences System (UI Health)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-0493","authenticated-orcid":false,"given":"Andrew","family":"Posen","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago, Retzky College of Pharmacy"},{"name":"University of Illinois Hospital and Health Sciences System (UI Health)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey056"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.39.1.99"},{"key":"e_1_3_5_4_2","unstructured":"ClinicalKey. Labetalol; drug monograph. https:\/\/www.clinicalkey.com\/pharmacology\/monograph\/337?sec=monmech. Accessed November 24 2024."},{"key":"e_1_3_5_5_2","volume-title":"Lexicomp Online\/Labetalol: Drug Information","year":"2024","unstructured":"Lexicomp Online\/Labetalol: Drug Information. Waltham, MA; 2024. https:\/\/online.lexi.com. Accessed November 26, 2024."},{"key":"e_1_3_5_6_2","unstructured":"Trandate (labetalol hydrochloride) Tablets. Sand Diego CA: Prometheus Laboratories Inc.; 2010. [package insert]."},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90141-9"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198937050-00002"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(71)90298-1"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/10826087409057366"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(16)31264-0"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2024.2348108"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.04.006"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2021-212294"},{"issue":"3","key":"e_1_3_5_18_2","first-page":"171","article-title":"Can metronidazole cause a disulfiram-like reaction? A case-control study propensity matched by age, sex, and ethanol concentration","volume":"122","author":"Feldman R","year":"2023","unstructured":"Feldman R, Jaszczenski R. Can metronidazole cause a disulfiram-like reaction? A case-control study propensity matched by age, sex, and ethanol concentration. Wis Med J. 2023;122(3):171-177.","journal-title":"Wis Med J"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1133584"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.13297"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251370870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251370870","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251370870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:54Z","timestamp":1777509234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251370870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/08971900251370870"],"URL":"https:\/\/doi.org\/10.1177\/08971900251370870","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]}}}